It was the first PARP-targeted PET imaging agent to be tested in the clinic and is currently involved in several phase I clinical trials, evaluating uptake in different cancers (Michel et al., 2017; Makvandi et al., 2018). This evidence concerns the gene PARP1 and cancer.